J Korean Med Assoc.  2016 Oct;59(10):775-784. 10.5124/jkma.2016.59.10.775.

Recent advances in ischemic stroke management

Affiliations
  • 1Department of Neurology, Inha University School of Medicine, Incheon, Korea. jhrha@inha.ac.kr

Abstract

There have been recent advances in the hyperacute treatment and secondary prevention of ischemic stroke. Thrombolysis with intravenous tissue plasminogen activator has been approved for a 3 to 4.5 hour time window, but the recent controversy over the optimal dose has not been resolved. Five endovascular trials published in 2015 have shown dramatically positive results. Regarding secondary prevention of ischemic stroke, a study suggesting the beneficial effect of a short course of dual antiplatelet therapy has been published. Non-vitamin K antagonist oral anticoagulation agents have been approved for stroke prevention in non-valvular atrial fibrillation. Here, we review these recent advances in ischemic stroke management.

Keyword

Stroke; Tissue plasminogen activator; Endovascular procedures; Platelet aggregation inhibitors; Anticoagulants

MeSH Terms

Anticoagulants
Atrial Fibrillation
Endovascular Procedures
Platelet Aggregation Inhibitors
Secondary Prevention
Stroke*
Tissue Plasminogen Activator
Anticoagulants
Platelet Aggregation Inhibitors
Tissue Plasminogen Activator
Full Text Links
  • JKMA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr